4.5 Review

Late HIV presentation: epidemiology, clinical implications and management

期刊

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 9, 期 10, 页码 877-889

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.11.106

关键词

delayed presentation; human immunodeficiency virus; immune suppression; late presenters; management; treatment response

资金

  1. Bristol-Myers Squibb
  2. Gilead Sciences
  3. Janssen-Cilag
  4. Abbott
  5. Data Safety and Monitoring Board
  6. Advisory Panels
  7. Merck Sharp Dohme
  8. Boehringer Ingelheim
  9. ViiV Healthcare

向作者/读者索取更多资源

Late presentation of HIV is common and is associated with several adverse outcomes including an increased risk of clinical progression, blunted immune recovery on highly active antiretroviral therapy and a greater risk of drug toxicity. Late presenters may have higher rates of poor adherence, exacerbated by the same factors that contribute to their late diagnosis, such as lack of knowledge about HIV and the benefits of highly active antiretroviral therapy. We review the definitions of, risk factors for and subsequent impact of late presentation. Evidence regarding how and when to start antiretroviral therapy, and with which agents, will be discussed, as well as issues surrounding vaccination and opportunistic infection prophylaxis for individuals with a low CD4 count. Finally, strategies to increase HIV testing uptake to reduce late presentation will be summarized.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据